Loading
A phase 3 trial of Tucidinostat, Sintilimab, Bevacizumab in colorectal cancer, run by Chipscreen Biosciences, Ltd., now recruiting.
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients is a phase 3 interventional study registered as NCT06497985 by Chipscreen Biosciences, Ltd., with 430 participants planned, started 2024-12-06 and due to reach its primary completion in 2028-05-31. Interventions recorded: Tucidinostat, Sintilimab, Bevacizumab, Fruquintinib. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tucidinostat (chidamide), Fruquintinib, Sintilimab, Anti-angiogenic therapy.
Shares Tucidinostat (chidamide), Fruquintinib, Sintilimab, Anti-angiogenic therapy.
Shares Tucidinostat (chidamide), Fruquintinib, Anti-angiogenic therapy, Immune checkpoint inhibitors.
Shares Sintilimab, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Sintilimab, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Fruquintinib, Sintilimab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Fruquintinib, Anti-angiogenic therapy, Colorectal cancer, Immune checkpoint inhibitors.
Shares Sintilimab, Bevacizumab, Monoclonal antibodies, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/